Biora Therapeutics, Inc. PROG
0.88 0.00 (+0.00%)
At closeMay 9, 2022, 12:00 AM EDT
0.84 Day range 0.92
52-week range unavailable
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 4.00
Ratings (-1m) 2 1 buy · 1 hold · 0 sell
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 2
- 2 months ago 2
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.12 | -0.13 – -0.12 | -0.56 | +78.6% | 107.00K | -99.6% | 2 |
| Next quarter | -0.12 | -0.13 – -0.11 | -1.23 | +90.2% | 0 | 0.0% | 2 |
| Current year | -0.42 | -0.49 – -0.36 | -2.57 | +83.7% | 100.00K | -99.6% | 2 |
| Next year | -0.37 | -0.49 – -0.26 | -0.42 | +11.9% | 0 | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2021 | HC Wainwright & Co. | Initiated | — | Buy |
| Jun 3, 2021 | Raymond James | Downgrade | Outperform | Market Perform |
| Jun 3, 2021 | Baird | Downgrade | Outperform | Neutral |
| May 17, 2021 | Wells Fargo | Maintained | — | Underweight |
| May 14, 2021 | Raymond James | Maintained | — | Outperform |
| Feb 8, 2021 | Wells Fargo | Downgrade | Overweight | Underweight |
| Nov 10, 2020 | Raymond James | Maintained | — | Outperform |
| Oct 23, 2020 | BTIG | Initiated | — | Buy |